1 / 1

Rucaparib(Rubraca)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

TABLET

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Rubraca is a poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of certain cancers associated with BRCA mutations. It works by targeting the DNA repair mechanisms of cancer cells, thereby inhibiting their ability to repair damaged DNA, leading to cell death, particularly in tumor cells. This drug is specifically indicated for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutations who have responded to prior platinum-based chemotherapy.

In addition to ovarian cancer, Rubraca has potential indications for prostate cancer treatment, though details regarding its use in this context are not explicitly mentioned in the provided specification. The primary therapeutic benefit lies in its ability to exploit synthetic lethality in tumor cells, making it a critical treatment option for patients with specific genetic profiles, particularly those with BRCA mutations.

Generic name

Rucaparib(Rubraca)

English name

Rucaparib

Alternative Names

Rubraca

Drug prices

Indications

RUBRACA (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the following:

Ovarian Cancer: Maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic) who have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and are in a complete or partial response to platinum-based chemotherapy.

Prostate Cancer: Indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with a BRCA mutation who have previously received at least one line of androgen receptor pathway inhibitor therapy.

Therapeutic Target

RUBRACA targets the enzyme poly (ADP-ribose) polymerase (PARP).

Active Ingredients

Rucaparib

Dosage form

TABLET

specifications

Description

RUBRACA (rucaparib) is an oral, small molecule, PARP inhibitor used in the treatment of cancers associated with BRCA mutations. By inhibiting PARP enzymes, rucaparib interferes with the repair of DNA damage in cancer cells, particularly in cells deficient in homologous recombination, such as those with BRCA mutations. This results in the accumulation of DNA damage and cancer cell death.

Rucaparib is presented in tablet form for easy oral administration.

Dosage and Administration

The dosage of RUBRACA varies depending on the indication. It is essential to follow the dosage recommendations strictly to avoid adverse reactions.

Ovarian Cancer:

Recommended starting dose: 600 mg (three 200 mg tablets) orally twice daily.

Treatment should be continued until disease progression or unacceptable toxicity.

Prostate Cancer:

Recommended starting dose: 600 mg (three 200 mg tablets) orally twice daily.

Treatment duration depends on clinical response and tolerability.

Adjustment for Renal Impairment:

Patients with moderate renal impairment (eGFR 30–59 mL/min/1.73 m²) should receive a reduced dose of 400 mg twice daily.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) should not receive RUBRACA.

Administration: Tablets should be taken with or without food. The tablets should be swallowed whole and not crushed, split, or chewed.

CATEGORY NAVIGATION